anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Levobunolol should be used with caution in patients with known hypersensitivity to other beta-adrenoceptor blocking agents. Use with caution in patients with known diminished pulmonary function.

Levobunolol should be used with caution in patients who are receiving a beta-adrenergic blocking agent orally, because of the potential for additive effects on systemic beta-blockade or on intraocular pressure. Patients should not typically use two or more topical ophthalmic beta-adrenergic blocking agents simultaneously.

Because of the potential effects of beta-adrenergic blocking agents on blood pressure and pulse rates, these medications must be used cautiously in patients with cerebrovascular insufficiency. Should signs or symptoms develop that suggest reduced cerebral blood flow while using levobunolol, alternative therapy should be considered.

In patients with angle-closure glaucoma, the immediate objective of treatment is to reopen the angle. This requires, in most cases, constricting the pupil with a miotic. Levobunolol Hydrochloride Ophthalmic Solution has little or no effect on the pupil. When levobunolol is used to reduce elevated intraocular pressure in angle-closure glaucoma, it should be followed with a miotic and not alone.
Patients that meet the inclusion criteria will be randomised and scheduled for surgery at least 2 weeks after the diagnosis/decision to proceed to surgery. This timeframe allows the implementation of a minimal 2 weeks (up to 4 weeks) multidisciplinary prehabilitation program. Prehabilitation program is composed of 4 elements: exercise training, nutritional intervention, correction of anaemia and smoking cessation. An individual treatment strategy will be proposed to the patient by a multidisciplinary team consisting of surgeon, anesthesiologist, dietitian and physiotherapist.
FIELD: chemistry; biochemistry. ^ SUBSTANCE: method involves evaporation of probiotic bacterial culture in a non-allergenic cultural substrate such as peptone and/or protein hydrolysate derived from plants and/or animals. The cultural substrate contains glucose and/or other mono- or disaccharides obtained from hydrolysis of complex polysaccharide. The second version of the method involves enzymatic pre-treatment of the cultural substrate to remove trace amounts of allergens arising from cross- or accidental contamination and growing at least one probiotic bacterial culture thereon. ^ EFFECT: invention enables to obtain a non-allergenic probiotic culture suitable for making a food product or a pharmaceutical composition meant for persons suffering from Coeliacs disease and especially sensitive to allergenic substances of gluten and/or lactic type. ^ 20 cl, 1 tbl
Chronic stress in early childhood, the result of living in poverty, exposure to violence, and/or experiencing abuse or neglect, undermines a child's development in ways that may have lasting consequences for well-being later in life. High quality parenting (i.e., responding sensitively when children are distressed, and following children's lead) appears to protect against the negative effects of chronic stress, likely by supporting the development of secure attachments and good self-regulation. Unfortunately, many caregivers living in poverty, through no fault of their own, are unable to parent in ways that provide this protection.

Children who face early adversity especially need nurturing, synchronous, and non-frightening care. The ABC intervention was developed to target these three parenting behaviors, with the goal of enhancing attachment relationships and regulatory capacities (Dozier et al., 2011). The ABC intervention is a manualized 10-session program delivered in the parent's home or other place of residence (e.g., homeless shelter). Sessions are videotaped for purposes of video feedback (i.e., showing brief clips back to parents for review of target behaviors), supervision, and fidelity monitoring.

Power of Two is a new non-profit organization in Brooklyn, NY that is implementing the ABC intervention for vulnerable families living in poverty. The purpose of the present study is to examine the effectiveness of ABC in the context of Power of Two's community-based implementation efforts. Using a short-term randomized control design, the investigators aim to replicate and extend previous findings regarding the efficacy of ABC. Participants will include 120 families with infants between 6 months and 20 months of age. Upon referral to the project, families will be randomly assigned to receive the ABC intervention immediately, or be put on a waitlist to receive the ABC intervention after approximately 3 months. Outcome assessments will include: (1) parent sensitivity (assessed at pre-intervention and follow-up), (2) attachment quality (assessed at follow-up), and (3) cortisol regulation (assessed at pre-intervention and follow-up). Additional variables will be included as moderators and covariates.
BACTROBAN NASAL is indicated for the eradication of nasal colonization with methicillin-resistant S. aureus in adult patients and health care workers as part of a comprehensive infection control program to reduce the risk of infection among patients at high risk of methicillin-resistant S. aureus infection during institutional outbreaks of infections with this pathogen.

NOTE:

  1. There are insufficient data at this time to establish that this product is safe and effective as part of an intervention program to prevent autoinfection of high-risk patients from their own nasal colonization with S. aureus.
  2. There are insufficient data at this time to recommend use of BACTROBAN NASAL for general prophylaxis of any infection in any patient population.
  3. Greater than 90% of subjects/patients in clinical trials had eradication of nasal colonization 2 to 4 days after therapy was completed. Approximately 30% recolonization was reported in 1 domestic study within 4 weeks after completion of therapy. These eradication rates were clinically and statistically superior to those reported in subjects/patients in the vehicle-treated arms of the adequate and well-controlled studies. Those treated with vehicle had eradication rates of 5% to 30% at 2 to 4 days post-therapy with 85% to 100% recolonization within 4 weeks.



All adequate and well-controlled trials of this product were vehicle-controlled; therefore, no data from direct, head-to-head comparisons with other products are available at this time.
Methods and devices for delivering variable amounts of a drug formulation directly from a drug delivery device without requiring point of use reconstitution as a separate mixing step are described herein. These methods and devices increase the convenience, speed and simplicity of administration of drug formulations. The devices mix two or more components in a constant mixing ratio effectively simultaneous to administration, and allow for variable doses while retaining the desired ratio of the components in each dose. The devices are particularly useful for administering drug formulations that are unstable at room temperature in liquid form. The methods described herein generally use conventional devices that have been modified to administer an unstable compound and provide acceptable storage stability. Typical devices include infusion sets, pump reservoirs, syringes, pens, vials and cartridges.
PURPOSE:To provide a skin-protecting agent for coating limbs having excellent water resistance and chemical resistance by containing a skin-coating agent and a powder. CONSTITUTION:A skin-protecting composition is combined with 0.1 to 20wt.% of a skin-coating agent of 2,000 to 300,000 molecular weight such as dimethylsiloxane polymer and 0.01 to 10wt.% of a hydrophobic powder of 90 to 180 deg. contact angle such as silicone powder. Combination of a skin-coating agent with a powder reduces skin roughening and shows excellent skin- protecting properties, even when the skin physically contacts with a large external area. The powder also has the action to reduce tackiness of the agent. The composition is preferably used in toilet water or in the gel form.
The invention relates to a cell-free graft comprising: (i) a coherent framework-forming matrix with an open porosity made of a biologically and pharmaceutically acceptable material, and; (ii) serum. According to a particularly preferred embodiment, the matrix also contains a gel. The invention also provides a method for producing a cell-free graft of this type during which the matrix and the gel, if present, is/are brought in contact with the serum. Optionally, the graft, together with the serum, can be dried.  Alternatively, the matrix and the gel, if present, are in a dry state before they are brought into contact with the serum. Lastly, the invention relates to the use of the cell-free graft for regenerating tissue and, in particular, for regenerating cartilage and/or bone.
Before KT application, their skin was shaved, cleaned with alcohol, and dried. Prior to application, the patient was seated and asked to flex their neck laterally to the contralateral side and to rotate their head to the same side. KTs (Ares®) tape was used. The first strip was a Y-strip representative of the supraspinatus, which was applied from its insertion to origin with paper off tension. A Y-strip refers to a section of tape that has a portion cut down the middle to produce 2 tails. In KTG, patients wore the KT for a 3-week duration (renewed twice a week periodically in this time).
Urethral stricture refers to the abnormal narrowing of the urethral lumen resulting from fibrosis that affects the urethral epithelium and underlying corpus spongiosum. The management of urethral stricture longer than 2 cm a major therapeutic challenge in clinics. Currently available surgical techniques require harvesting of grafts from autologous sites. However, there are numerous disadvantages associated with autografts, such as limited availability and variable quality, donor site morbidity, increased risk of surgical complications; thereby the application of this method is especially limited for large defects.

The hypothesis of this study is that the small intestinal submucosa graft can be used as an alternative biomaterial to buccal mucosa for substitution urethroplasty in urethral stricture patients. The aim of this study is to assess safety and efficacy of surgical treatment of patients with anterior urethral stricture using a small intestinal submucosa graft. The follow-up time for all patients in this study was 5 years. The follow-up regimen includes retrograde and pericatheter urethrography, voiding cystourethrography, uroflowmetry, cystoscopy, and voiding symptoms monitoring. Telephone follow-up will take place in between these assessments.
Experimental: Add-on Mirabegron Patients without symptom improvement or with partial response under intensive behavioural protocol and medical therapy (at least 2 different antimuscarinic agents) will be recruited. They will keep the antimuscarinic and Mirabegron will be added (dual therapy).
INTRODUCTION: Neovascular age-related macular degeneration (nAMD) represents a leading cause of severe visual impairment in individuals over 50 years of age in developed nations. Intravitreal anti-vascular endothelial growth factor (VEGF) injections have become the standard of care for treating nAMD; however, monthly or bimonthly dosing represents significant time and cost burden due to the disease's chronic nature and limited medication half-life.
AREAS COVERED: This review summarizes innovative therapeutics and delivery methods for nAMD. Emerging methods for extended drug delivery include high molar concentration anti-VEGF drugs, intravitreal sustained-release polymers and devices, reservoirs for intravitreal delivery, suprachoroidal delivery of small molecular suspensions and gene therapy biofactories. In addition to VEGF-A, therapies targeting inhibition of VEGF-C and D, the angiopoetin-2 (Ang-2)/Tie-2 pathway, tyrosine kinases, and integrins are reviewed.
EXPERT OPINION: The evolving therapeutic landscape of nAMD is rapidly expanding our toolkit for effective and durable treatment. Recent FDA approvals of faricimab (Vabysmo) and high-dose aflibercept (Eylea HD) for nAMD with potential extension of injection intervals up to four months have been promising developments for patients and providers alike. Further research and innovation, including novel delivery techniques and pharmacologic targets, is necessary to validate the efficacy of developing therapeutics and characterize real-world outcomes, demonstrating promise in expanding treatment durability.
A multi-functional chimeric hematopoietic protein comprising an amino acid sequence of the formula: R1-L1-R2,   R2-L1-R1,   R1-R2   or R2-R1 Wherein R1 and R2 are independently selected from the group consisting of; (I) A human EPO receptor agonist polypeptide, comprising a modified EPO as shown in Sequence ID 464, wherein 1-6 amino acids from the N-terminus and/or 1-5 from the C-terminus are optionally deleted. The N-terminus is joined to the C-terminus directly or through a linker (L2). (II) A human stem cell factor receptor agonist polypeptide comprising a modified stem cell factor as shown in Sequence ID 465, wherein 1-23 amino acids are optionally deleted from the C-terminus. The N-terminus is joined to the C-terminus directly or through a linker (L2). (III) A human flt-3 receptor agonist polypeptide comprising a modified flt-3 ligand as shown in Sequence ID 466, wherein 1-7 amino acids are optionally deleted from the C-terminus. The N-terminus is joined to the C-terminus directly or through a linker (L2). (IV) A human G-CSF polypeptide comprising a modified human G-CSF as shown in Sequence ID 858, wherein Xaa may be replaced with any of the disclosed amino acids and 1-11 amino acids and/or 1-5 amino acids are optionally deleted from the C-terminus. The N-terminus is joined to the C-terminus directly or through a linker (L2). (V) A human IL-3 polypeptide comprising a modified human IL-3 as shown in Sequence ID 859 whereupon the modified IL-3 is circularly permuted, wherein Xaa may be replaced with any of the disclosed amino acids and 1-14 amino acids and/or 1-15 amino acids are optionally deleted from the C-terminus and amino acids 0-44 designated Xaa are different to the corresponding native human IL-3 (1-133). The N-terminus is joined to the C-terminus directly or through a linker (L2). (VI) A human c-mpl ligand polypeptide comprising a modified human c-mpl ligand as shown in Sequence ID 860, wherein Xaa may be replaced with any of the disclosed amino acids. The N-terminus is joined to the C-terminus directly or through a linker (L2). (VII) A human IL-3 polypeptide comprising a modified human IL-3 as shown in Sequence ID 859, wherein Xaa may be replaced with any of the disclosed amino acids and 1-14 amino acids and/or 1-15 amino acids are optionally deleted from the C-terminus and amino acids 0-44 designated Xaa are different to the corresponding native human IL-3 (1-133). The N-terminus is joined to the C-terminus directly or through a linker (L2). (VIII) A factor selected from the group consisting of a colony stimulating factor, a cytokine, a lymphokine, an interleukin and a hematopoietic growth factor; and L1 is a linker capable of linking R1 to R2, with the proviso that R1 and R2 is selected from the polypeptide of the Formula (I), (II) or (III).
The present disclosure is directed to the use of PF4 alone or anti-PF4 antibodies alone or the combination thereof to treat sepsis. Neutrophils release their histone-coated DNA termed neutrophil extracellular traps (NETs) during sepsis and related inflammatory disorders. NETs are broken down and release NET degradation products (NDPs) like histone that are toxic and contribute to the morbidity and mortality in sepsis and related inflammatory disorders. The inventors have shown that a native platelet protein, platelet factor 4 (PF4), which is highly positively-charged, compacts NETs that are in turn highly negatively-charged. These compact NETs are resistant to NDP release and breakdown by circulating DNases. PF4 protects against this lysis and NDP release and improves outcome. The inventors also found that an antibody to PF4 that cross-binds PF4 on NETs further protects against lysis and NDP release. Such antibodies, perhaps supplemented with additional PF4, are therapeutic candidates for treatment of sepsis.
<P>PROBLEM TO BE SOLVED: To provide a high-precision tailor-made medicine prescription system for prescribing medicine in terms of selection, dosage and dose regimen according to the genetic information of a patient without causing a problem of the violation of privacy.  <P>SOLUTION: A personal gene integrating database 102 stores personal gene information while associating it with a patient ID. A gene analysis information register means 113 of a gene analysis institution terminal 30 registers the personal gene information analyzed by a gene analysis institution to the personal gene integrate database 102. A medical institution terminal 10 conducts settlement process for paying the registration cost of the personal gene information from the patient to the gene analysis institution and confirms the will of the patient whether the view of the gene information is permitted or not. The medical institution terminal 10 accesses the personal gene integrating database 102 via the Internet 100 in the case that the will of view permission is confirmed and conducts the search of the gene information by using the patient ID of the patient and displays the searched gene information for a doctor in charge.  <P>COPYRIGHT: (C)2006,JPO&NCIPI
PURPOSE:To provide an antiulcer agent exhibiting excellent drug action especially against stress ulcers, by using a specific compound known as a cyanine- type photosensitive dye and remedy for frostbite and scald as an active component. CONSTITUTION:A compound of formula (R is H or 1-4C alkyl; X is halogen) is used as an antiulcer agent. A concrete example of the compound is 4,4'-{3-{2-[1-ethyl-4-( 1-H )quinolidene]ethylidene}}propenylene[bis(1-ethylquinoli nium iodide)]. It is administered preferably by oral administration at a dose of preferably 80-200mug/kg. The compound of formula exhibits high drug action as a remedy for central ulcer. The compound can be produced by reacting aniline with methyl vinyl ketone to obtain lepidine, separately preparing a diformyl derivative of the compound of formula by Vilsmeier reaction, reacting the derivative with the above-obtained lepidine and reacting the reaction product with desired alkyl halide.
The invention discloses a catechu-containing traditional Chinese medicine preparation and a preparation method thereof. The catechu-containing traditional Chinese medicine preparation comprises, by mass, 60-100 parts of catechu, 30-40 parts of pseudo-ginseng powder, 15-25 parts of root of kudzu vine, 20-30 parts of rheum officinale, 15-30 parts of root of large-flowered skullcap, 25-35 parts of Radix Astragali, 10-15 parts of Chinese angelica, 80-100 parts of xylitol and 6-8 parts of magnesium stearate. The preparation method utilizes catechu and dry ginger as raw materials, does not contain hormones and antibiotics in Western medicines, and does not cause drug resistance. A study proves that the natural plants adopted by the preparation method have no obvious toxic or side effects, have high safety, can be absorbed fast, can produce effects fast and are convenient for use. The catechu-containing traditional Chinese medicine preparation has effects of clearing heat, generating body fluid, stopping bleeding, protecting liver, benefiting gallbladder, reducing blood pressure, improving user immunity and resisting pathogenic organisms. The preparation method has a low cost and simple processes and can be used widely.
Participants will receive 3000 centi-Gray (cGy) WBRT in 10 single daily fractions over 12 to 14 days (300 cGy / fraction) followed by standard of care therapy at the discretion of the treating oncologist starting no earlier than 2 weeks after completion of WBRT. The participants will be followed during the treatment until the halting of standard of care for any reason (central nervous system \[CNS\] or extra-cranial tumor progression, unacceptable toxicity, change of therapeutic strategy, withdrawal of participant consent, or death).
Each Iscador® P therapy begins with a dose finding phase related to the drug' immunogenicity. In this phase, gradually increasing doses are used to determine the optimum individual dose response of the patient and to prevent excessive toxicity. The Iscador® P will be administered three times per week by subcutaneous injections (M,W,F) into the subcutaneous tissue of the thigh or abdomen. Treatment is administered according to a series of escalating doses that are given each of the three days in a week for 7 doses. There are 3 different series (Series 0, 1, and 2) and there are 7 dose vials in each series. Once the patient has reached their maximum tolerated dosing series, that series is used as the treatment regimen for the remaining weeks to a total duration of 52 weeks (13 cycles) or until disease progression. Each cycle is 4 weeks.
The concept that all patients with HIV-1 infection require continuous and indefinite antiretroviral therapy (ART) has been questioned. There are both theoretical reasons and supporting empiric evidence that suggest that discontinuing ART should not select for EFV-resistance. In Dupont Protocol 006, antiretroviral-naive patients were randomized to receive EFV, ZDV, and 3TC. This regimen was associated with an excellent and sustained virologic response. It is certain that many patients in this study were able to maintain sustained suppression of HIV-1 RNA to below limits of detection despite missing occasional doses of all medications. Since therapy with ZDV and 3TC alone is unlikely to maintain virologic control, emergence of substantial high-level EFV resistance should have led to virologic failure. The fact that there were relatively few virologic failures in that study provides indirect but strong evidence that simultaneous discontinuation of EFV, ZDV, and 3TC is unlikely to be associated with emergence of EFV resistance. Many individuals discontinue antiretroviral therapy because of adverse effects. This study provides the opportunity to determine whether the virologic response of patients who discontinue antiretroviral therapy will be compromised.

Participants will discontinue their EFV. Other antiretroviral drugs in the patients' regimens may be continued for up to three days after the last EFV dose. Patients will not resume EFV or other antiretroviral agents for at least 28 days after stopping EFV, unless the CD4 cell count declines to a level that indicates the need to resume therapy. Throughout the study, patients will have blood drawn on specified days for plasma EFV assays, intracellular NRTI-TP assays, and demonstration of EFV resistance. After patients have been off their antiretrovirals for at least four weeks, they may choose to restart their ART, start a new regimen, or discontinue their ART. Patients who restart their ART need to come to the clinic seven days after restarting to have blood drawn. After plasma EFV assays have been completed and HIV resistance has not been demonstrated, three patients will have a clonal analysis performed.